Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   15/12/2025
752,62 USD (+1,53%)
(+1,53%)   15/12/2025

12 maart 2025 · Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem · Persbericht

6 maart 2025 · Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

5 maart 2025 · SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals · Persbericht

5 maart 2025 · CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025 · Persbericht

4 maart 2025 · Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) · Persbericht

29 mei 2024 · Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors · Persbericht

13 maart 2024 · High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization · Persbericht

24 januari 2024 · Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards · Persbericht

8 januari 2024 · Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries · Persbericht

19 mei 2023 · High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 · Persbericht

15 maart 2023 · Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease · Persbericht

24 januari 2023 · Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition · Persbericht

23 december 2022 · Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer · Persbericht

21 december 2022 · Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine · Persbericht

19 december 2022 · Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

16 december 2022 · Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis · Persbericht

15 december 2022 · Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis · Persbericht

12 december 2022 · Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial · Persbericht

12 december 2022 · Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma · Persbericht

12 december 2022 · Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year · Persbericht

Mijn selecties